levofloxacin has been researched along with zithromax in 162 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (zithromax) | Trials (zithromax) | Recent Studies (post-2010) (zithromax) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 6,964 | 1,263 | 3,790 |
| Protein | Taxonomy | levofloxacin (IC50) | zithromax (IC50) |
|---|---|---|---|
| 30S ribosomal protein S6 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S7 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L15 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L10 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L11 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L19 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L1 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L20 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L27 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L28 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L29 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L31 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L32 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L33 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L34 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L35 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L36 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S10 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S11 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S12 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S13 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S16 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S18 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S19 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S20 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S2 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S3 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S4 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S5 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S8 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S9 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L13 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L14 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L16 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L23 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S15 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L17 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L21 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L30 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L6 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S14 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S17 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S1 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L18 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L2 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L3 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L24 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L4 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L22 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L5 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S21 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L25 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | 0.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (3.09) | 18.2507 |
| 2000's | 86 (53.09) | 29.6817 |
| 2010's | 56 (34.57) | 24.3611 |
| 2020's | 15 (9.26) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Chan, YY; Chua, KL; Ong, YM | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Ardanuy, C; Bouza, E; Calatayud, L; Cercenado, E; Fenoll, A; Liñares, J; Martín, R; Pallares, R | 1 |
| Baba, S; Billal, DS; Fujihara, K; Hotomi, M; Nishimura, T; Suzuki, K; Yamanaka, N | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Kosowska-Shick, K; McGhee, P | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Brown, SD; Critchley, IA; Janjic, N; Tillotson, GS; Traczewski, MM | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Chiba, N; Hasegawa, K; Iwata, S; Matsubara, K; Morozumi, M; Nakayama, E; Sunakawa, K; Takayanagi, R; Ubukata, K | 1 |
| Brémont, S; Courvalin, P; Damier-Piolle, L; Lambert, T; Magnet, S | 1 |
| Danese, P; DeVito, J; Franceschi, F; Lawrence, L; Sutcliffe, J | 1 |
| Appelbaum, PC; Ednie, LM; Hawser, S; Lociuro, S; Smith, K | 1 |
| Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Brown, SD; Critchley, IA; Jacobs, MR; Janjic, N; Tillotson, GS; Traczewski, MM | 1 |
| Crabb, DM; Duffy, LB; Waites, KB | 2 |
| Esteban, J; Fernández-Martínez, AI; Fernández-Roblas, R; Gadea, I; García-Almeida, D; Martín-de-Hijas, NZ | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Artemenko, NK; Tetz, GV; Tetz, VV | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Appelbaum, PC; Beachel, L; Clark, C; Dewasse, B; Kosowska-Shick, KM; McGhee, P; Nagai, K | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Dal-Ré, R; García-de-Lomas, J; García-Delafuente, C; Iriarte, V; Martín-Herrero, JE; Mazón, A; Pérez-Trallero, E; Robles, P | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Biedenbach, DJ; Castanheira, M; Jones, RN | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Baldelli, R; Cevenini, R; D'Antuono, A; Delucca, F; Di Francesco, A; Donati, M; Moroni, A; Shurdhi, A | 1 |
| Achorn, C; Chen, CL; Clark, RB; Deng, Y; Fyfe, C; Grossman, TH; He, M; Hogan, PC; Hunt, DK; O'Brien, WJ; Plamondon, L; Rönn, M; Sutcliffe, JA; Xiao, XY; Zhu, Z | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Alm, R; Basarab, GS; Bist, S; Dangel, PB; Eakin, AE; Garner, CE; Green, O; Hauck, S; Hill, PJ; Hull, K; Illingworth, R; Manchester, JI; Rooney, M; Sherer, BA; Uria-Nickelsen, M; Zhou, F | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Steenbergen, J; Tanaka, SK; Villano, S | 1 |
| Aldrich, C; Brody, S; Cushman, M; Fan, BZ; Hiasa, H; Liang, JH; Lv, W; Yang, ZY | 1 |
| Amada, H; Endo, M; Hitaka, K; Kamitani, M; Masuko, A; Mihara, Y; Mima, M; Ohtake, N; Sugiyama, H; Takata, I; Takeuchi, T; Tamura, Y; Tanaka-Yamamoto, N; Ushiyama, F; Wada, R | 1 |
| Citron, DM; Goldstein, EJ; Nesbit, CA | 1 |
| Citron, DM; Claros, MC; Goldstein, EJ; Hunt Gerardo, S | 1 |
| Appelbaum, PC; Jacobs, MR; Visalli, MA | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| Appelbaum, PC; Jacobs, MR; Lin, G; Spangler, SK | 1 |
| Coleman, EJ; Mandell, GL | 1 |
| Bush, K; Fogarty, C; Goldschmidt, R | 1 |
| Doyle, E; Edelstein, MA; Edelstein, PH; Shinzato, T | 1 |
| Hammerschlag, MR; Kutlin, A; Roblin, PM | 1 |
| Chimura, T | 1 |
| Bosso, JA; Enzweiler, KA; Friedrich, LV; Hoban, D; Wagner, D; White, RL | 1 |
| Bahal, N; Frank, E; Freitag, S; Kahn, JB; Kinasewitz, G; Liu, J; Moran, GJ; Olson, WH; Oross, MP; Reichl, V; Tennenberg, A; Wiesinger, BA | 1 |
| Hammerschlag, MR; Kutlin, A; Reznik, T; Roblin, PM | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
| Amsden, GW; Baird, IM; Simon, S; Treadway, G | 1 |
| Malcolm, C; Marrie, TJ | 1 |
| Critchley, IA; Evangelista, AT; Jones, ME; Karlowsky, JA; Noel, GJ; Sahm, DF; Thornsberry, C | 1 |
| Danziger, LH; Gotfried, MH; Rodvold, KA | 1 |
| Itoh, Y; Kikuchi, K; Nakanishi, K; Nakao, S; Ohsaki, Y; Osanai, S; Saito, K; Sato, M; Tachibana, M; Takahashi, T; Toyoshima, E | 1 |
| Shen, M; Zhao, Y; Zhou, LQ | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yamanaka, N; Yoshimori, K | 1 |
| Adachi, JA; DuPont, HL; DuPont, MW; Ericsson, CD; Jiang, ZD; Knirsch, C; Martinez-Sandoval, F | 1 |
| Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Hammerschlag, MR; Hawser, S; Islam, K; Kohlhoff, SA; Reznik, T; Roblin, PM | 1 |
| Good, CE; Jakielaszek, C; Koeth, LM; Saunders, KA | 1 |
| Marrie, TJ | 1 |
| Arenoso, H; Bantar, C; Caruso, N; Fernández Canigia, L; Nicola, F; Soutric, J | 1 |
| Alou, L; Cafini, F; Prieto, J; Sevillano, D; Valero, E | 1 |
| Caronzolo, D; Colleoni, F; Fraschini, F; Grosso, S; Lucini, V; Pannacci, M; Scaglione, F | 1 |
| Abdulla, RH; Amsden, GW; Andrews, CP; de Caprariis, PJ; Knirsch, CA; Lode, H; Mandell, LA; McIvor, A; Niederman, MS; Vrooman, PS; Zervos, M | 1 |
| Berry, V; Hoover, J; Singley, C; Woodnutt, G | 1 |
| Armstrong, EP; Malone, DC; Ramachandran, S; Skrepnek, GH | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Consolazio, A; Crispino, P; Iacopini, F; Nardi, F; Palladini, D; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M | 1 |
| Fugit, RV; Glasheen, JJ; Prochazka, AV | 1 |
| Breen, JD; Emparanza, P; Lesinskas, E; Murray, JJ; Tawadrous, M | 1 |
| Breen, JD; Camere, MA; D'Ignazio, J; Jorgensen, D; Lewis, DE | 1 |
| Harnett, J; Matchar, DB; Samsa, GP; Wilson, J | 1 |
| Cho, YK; Jeon, WK; Kang, MS; Kim, BI; Kim, HJ; Oh, SY; Park, DI; Park, JH; Sohn, CI; Yoo, TW; Yun, JW | 1 |
| Blasi, F; Tarsia, P | 1 |
| Martinez, FJ | 1 |
| Lück, PC; Steinert, M | 1 |
| Pedro-Botet, L; Yu, VL | 1 |
| Mikamo, H; Tamaya, T; Tanaka, K; Watanabe, K | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Adam, HJ; Laing, N; Mayer, M; Zhanel, GG | 1 |
| Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D | 1 |
| Komori, K; Nakada, N; Suzuki, Y; Tanaka, H; Yasojima, M | 1 |
| García-Cruz, A; Mateu, L; Pedro-Botet, ML; Rey-Joly, C; Roure, S; Sabria, M; Sopena, N; Tural, C | 1 |
| Armstrong, A; Baqar, S; Bodhidatta, L; Faix, DJ; Fox, A; Hshieh, P; Lawler, JV; Lebron, C; Lewis, M; Maley, EA; Mason, C; Nayak, G; Pang, LW; Pitarangsi, C; Sanders, JW; Scott, DA; Tribble, DR | 1 |
| Erkin, G; Isik, SR; Kalyoncu, AF; Karakaya, G | 1 |
| LaPlante, KL; Mersfelder, TL; Quilliam, BJ; Ward, KE | 1 |
| de Caprariis, PJ; Marple, BF; Reisman, A; Roberts, CS | 1 |
| Aguilar, L; Alou, L; Echeverría, O; Giménez, MJ; González, N; Martín, JE; Prieto, J; Sevillano, D; Torrico, M; Valdés, L | 1 |
| Frenck, RW; Johnston, JR; Monteville, MR; Putnam, SD; Riddle, MS; Rockabrand, DM; Sanders, JW; Tribble, DR; Ulukan, S | 1 |
| Dubrovskaia, NV; Dvoretskiĭ, LI; Filimonova, OIu; Grudinina, SA; Iakovlev, SV; Sidorenko, SV | 1 |
| Attridge, RT; Fisher, A; Frei, CR; Jaso, TC; Makos, BR; Mody, SH; Mortensen, EM; Oramasionwu, CU; Raut, MK; Restrepo, MI; Ruiz, AD; Ruiz, JL; Schein, JR | 1 |
| Ambruzs, M; Fisher, AC; Nord, CE; Peterson, J | 1 |
| Biernat-Sudolska, M; Drzewiecki, A; Rojek-Zakrzewska, D | 1 |
| Rapp, RP | 1 |
| Carratalà, J; Garcia-Vidal, C | 1 |
| Arnold, F; Griffin, AT; Peyrani, P; Wiemken, T | 1 |
| Baddour, LM; Edelstein, PH; Han, JH; Harada, S; Nguyen, JC | 1 |
| Bobyleva, ZD; Leshchenko, IV | 1 |
| Garlaschi, MC; Magri, V; Markotić, A; Marras, E; Perletti, G; Restelli, A; Skerk, V | 1 |
| Hashimoto, J; Hayashi, K; Ichihara, K; Iwasawa, A; Kurimura, Y; Satoh, T; Sunaoshi, K; Suzuki, N; Takahashi, S; Takeda, K; Tsukamoto, T | 1 |
| Ishii, Y; Kimura, S; Sato, T; Tateda, K; Yamaguchi, K | 1 |
| Kim, SJ; Toma, HS | 1 |
| An, J; Hao, XY; Li, ZS; Wang, GC; Zuo, GY | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Dan, M; Rosenberg, S; Samra, Z | 1 |
| Bian, ZQ; Han, J; Li, Y; Wang, GC; Zhang, YL; Zuo, GY | 1 |
| Blanco, AR; Papa, V; Spoto, CG; Sudano Roccaro, A | 1 |
| Aboud, C; Algood, H; Boyd, AS; Braun, N; Burke, VE; Drake, WP; Isom, J; Kaminski, N; King, LE; Oswald-Richter, K; Pandit, KV; Richmond, BW; Taylor, T; Yu, C | 1 |
| Drake, WP; Isom, JM; Oswald-Richter, K; Richmond, BW; Shipley, GR; Worrell, JA; Yu, C | 1 |
| Araki, I; Baba, M; Kageyama, S; Nakano, E; Okada, Y; Yamashita, H | 1 |
| Hammerschlag, MR; Huband, MD; Kohlhoff, SA | 1 |
| Aubart, K; Butler, D; Dubois, J; Dubois, M; Martel, JF | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Bennett, CL; Jacob, S; Li, M; Lu, ZK; Rao, GA; Sutton, SS; Yuan, J | 1 |
| Crabb, DM; Duffy, LB; Huband, MD; Waites, KB | 1 |
| Fan, WG; Wang, L; Zhang, QS | 1 |
| Ferrari, F; Lococo, F; Mengoli, MC; Montanari, G; Rossi, G; Spagnolo, P | 1 |
| Ahmed, F; Barrow, R; Bornstein, M; Risley, JF; Simmons, S; Workowski, KA | 1 |
| Burgos, J; Carratalà, J; Falco, V; Garcia-Vidal, C; Martin, MT; Sanchez-Rodriguez, I; Simonetti, AF; Viasus, D | 1 |
| Deguchi, T; Hatazaki, K; Ito, S; Kondo, H; Mizutani, K; Nakane, K; Nakano, M; Ohinishi, M; Shimuta, K; Tsuchiya, T; Yasuda, M; Yokoi, S | 1 |
| Tribble, DR | 1 |
| Hardin, JW; Hyche, S; Magagnoli, J; Sutton, SS | 1 |
| Connor, P; Danboise, B; Fraser, J; Gutierrez, RL; Hulseberg, C; Hutley, EJ; Lalani, T; Porter, CK; Riddle, MS; Simons, MP; Swierczewski, B; Tribble, DR | 1 |
| Ba-Thein, W; Pan, H | 1 |
| Bulkow, L; Gordon, K; Stevens, R; Westley, B | 1 |
| Dadras, O; Dadsetan, B; Heidari, H; Izadi, M; Jafari, S; Mazaheri, E; Najafi, Z; SeyedAlinaghi, S; Voltarelli, F | 1 |
| Hammerschlag, MR; Huerta, N; Kohlhoff, SA | 1 |
| Ishiguro, N; Konno, S; Matsumoto, M; Nagaoka, K; Nishimura, M; Suzuki, M; Takahashi, K; Takashina, T | 1 |
| Cai, T; Magri, V; Montanari, E; Perletti, G; Stamatiou, K; Trinchieri, A | 1 |
| Hatakeyama, S; Matsui, H; Morisawa, Y; Sasabuchi, Y; Sasahara, T; Suzuki, J; Yamada, T; Yasunaga, H | 1 |
| Macía, M; Navarro, D; Romay, AB; Trastoy, R; Treviño, M; Veiga, E | 1 |
| Alishlash, AS; Atkinson, TP; Leal, SM; Schlappi, C; Waites, KB; Xiao, L | 1 |
| Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
| Abel, K; Ayers, GD; Baughman, RP; Bernard, GR; Crouser, ED; Culver, DA; Ding, T; Drake, WP; Green, A; James, WE; Judson, MA; Kerrigan, A; Sesay, A | 1 |
| Ammar, NS; Baddour, MM; Barakat, HS; El-Metwally, HAE; Meheissen, MA; Owais, HM | 1 |
| Allen, GP; Deao, KM; Hill, SA; Schipelliti, SM; Tran, T | 1 |
| Chen, Q; Fan, X; Guo, YL; Li, Q; Lv, XT; Zhao, C | 1 |
| Al-Khatib, SM; Assimon, MM; Brookhart, MA; Flythe, JE; Pun, PH; Wang, L; Weber, DJ; Winkelmayer, WC | 1 |
| Güler, N; Süleyman, A; Tamay, Z | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| Crumrine, M; Hewitt, JA; Slay, RM | 1 |
| Bulychev, VV; Bulycheva, EV; Pashkova, NA | 1 |
| Chasqueira, MJ; Cruz, C; Fernandes, F; Paixão, P; Rodrigues, L; Santos, R | 1 |
| Alvear, G; Martínez, B; Ramírez, V; Santibáñez, L; Sepúlveda, R | 1 |
| Cheng, WH; Ho, CH; Su, PY | 1 |
10 review(s) available for levofloxacin and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Drug Discovery; Humans; Microbial Sensitivity Tests; Molecular Conformation; Tetracyclines | 2016 |
Value of short-course antimicrobial therapy in community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Microspheres; Ofloxacin; Pneumonia; Time Factors; Treatment Outcome | 2005 |
Acute exacerbation of chronic bronchitis: expanding short-course therapy.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Azithromycin; Bronchitis; Clinical Trials as Topic; Confidence Intervals; Double-Blind Method; Drug Administration Schedule; Humans; Levofloxacin; Microspheres; Middle Aged; Ofloxacin; Severity of Illness Index; Treatment Outcome | 2005 |
[Pathogenesis, diagnosis and therapy of Legionella infections].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Aza Compounds; Azithromycin; Ciprofloxacin; Diagnosis, Differential; DNA, Bacterial; Fluoroquinolones; Humans; Incidence; Legionella; Legionella pneumophila; Legionellosis; Legionnaires' Disease; Levofloxacin; Moxifloxacin; Ofloxacin; Polymerase Chain Reaction; Quinolines; Serotyping; Virulence | 2006 |
Legionella: macrolides or quinolones?
Topics: Animals; Anti-Infective Agents; Azithromycin; Clinical Trials as Topic; Humans; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones | 2006 |
An update on Legionella.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Community-Acquired Infections; Cross Infection; Germany; Humans; Incidence; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Ofloxacin; United States | 2010 |
Relapsing Legionella pneumophila cellulitis: a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Cellulitis; Fatal Outcome; Female; Humans; Immunocompromised Host; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Ofloxacin; Recurrence | 2010 |
Cardiac risks associated with antibiotics: azithromycin and levofloxacin.
Topics: Anti-Bacterial Agents; Azithromycin; Death; Humans; Levofloxacin; Long QT Syndrome | 2015 |
Legionella micdadei Aquaticum Infection: a Case Report and Literature Review.
Topics: Adult; Azithromycin; Erythromycin; Female; Humans; Legionella; Legionellaceae; Legionellosis; Levofloxacin; Male; Middle Aged; Pneumonia | 2022 |
22 trial(s) available for levofloxacin and zithromax
| Article | Year |
|---|---|
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Severity of Illness Index | 2002 |
Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Bronchitis, Chronic; Double-Blind Method; Female; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ofloxacin | 2003 |
Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.
Topics: Adult; Algorithms; Anti-Bacterial Agents; Anti-Infective Agents; Area Under Curve; Azithromycin; Blood Urea Nitrogen; Bronchi; Bronchoalveolar Lavage Fluid; Bronchoscopy; Chromatography, High Pressure Liquid; Epithelium; Female; Humans; Injections, Intravenous; Levofloxacin; Lung; Macrophages, Alveolar; Male; Ofloxacin | 2003 |
Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Diarrhea; Double-Blind Method; Female; Humans; Levofloxacin; Male; Mexico; Ofloxacin; Travel | 2003 |
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Azithromycin; Bronchoalveolar Lavage Fluid; Extravascular Lung Water; Female; Fluoroquinolones; Humans; Levofloxacin; Lung; Macrophages, Alveolar; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Urea | 2004 |
Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Azithromycin; Cefuroxime; Community-Acquired Infections; Critical Pathways; Drug Therapy, Combination; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Middle Aged; Ofloxacin; Oxygen Inhalation Therapy; Pneumococcal Infections; Pneumonia; Pneumonia, Bacterial; Treatment Outcome | 2004 |
An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae.
Topics: Adult; Amoxicillin; Analysis of Variance; Azithromycin; Blood Bactericidal Activity; Colony Count, Microbial; Cross-Over Studies; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Probability; Sensitivity and Specificity; Serum Bactericidal Test; Single-Blind Method; Statistics, Nonparametric; Streptococcus pneumoniae; Sulbactam | 2004 |
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Azithromycin; Canada; Ceftriaxone; Community-Acquired Infections; Drug Administration Schedule; Female; Germany; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome; United States | 2004 |
One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Patient Compliance; Treatment Outcome | 2005 |
Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Chemistry, Pharmaceutical; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; International Cooperation; Levofloxacin; Male; Maxillary Sinusitis; Microspheres; Middle Aged; Ofloxacin; Probability; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Chemistry, Pharmaceutical; Community-Acquired Infections; Double-Blind Method; Female; Humans; Incidence; Levofloxacin; Male; Microspheres; Middle Aged; Ofloxacin; Outpatients; Pneumonia; Serologic Tests; Time Factors; Treatment Outcome | 2005 |
A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Costs and Cost Analysis; Drug Therapy, Combination; Female; Home Care Services; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; United States | 2005 |
[Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication].
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin | 2006 |
Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Campylobacter jejuni; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Bacterial; Dysentery; Escherichia coli Infections; Female; Humans; Levofloxacin; Male; Military Personnel; Ofloxacin; Salmonella Infections; Thailand | 2007 |
Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey.
Topics: Adult; Azithromycin; Campylobacter Infections; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Escherichia coli Infections; Feces; Female; Humans; Levofloxacin; Loperamide; Male; Military Personnel; Nausea; Ofloxacin; Salmonella Infections; Time Factors; Travel; Turkey; United States | 2007 |
Levofloxacin versus azithromycin on the oropharyngeal carriage and selection of antibacterial- resistant streptococci in the microflora of healthy adults.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Microbial Viability; Ofloxacin; Oropharynx; Streptococcaceae; Streptococcal Infections; Young Adult | 2009 |
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Levofloxacin; Middle Aged; Moxifloxacin; Nasopharynx; Ofloxacin; Prospective Studies; Quinolines; Staphylococcal Infections | 2011 |
Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; CD4-Positive T-Lymphocytes; Chronic Disease; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Rifampin; Sarcoidosis; Severity of Illness Index; Single-Blind Method; Skin Diseases; Transcriptome; Treatment Outcome; Young Adult | 2013 |
Male Paraurethral Duct Infection and Subsequent Paraurethral Duct Dilation.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Humans; Levofloxacin; Male; Middle Aged; Nitrofurantoin; Urethra; Urethral Diseases; Young Adult | 2015 |
Trial Evaluating Ambulatory Therapy of Travelers' Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide.
Topics: Acute Disease; Adult; Afghanistan; Anti-Bacterial Agents; Azithromycin; Diarrhea; Djibouti; Double-Blind Method; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Honduras; Humans; Kenya; Levofloxacin; Loperamide; Male; Military Personnel; Travel; Treatment Outcome | 2017 |
Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Asia; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Pneumonia; Prospective Studies; Treatment Outcome | 2018 |
Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Azithromycin; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Ethambutol; Female; Humans; Levofloxacin; Male; Middle Aged; Respiratory Function Tests; Rifabutin; Sarcoidosis, Pulmonary | 2021 |
130 other study(ies) available for levofloxacin and zithromax
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
Topics: Anti-Infective Agents; Burkholderia pseudomallei; Cells, Cultured; Drug Synergism; Humans; Lung; Macrophages; Melioidosis; Microbial Sensitivity Tests; Phenothiazines; Proton Pump Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
Topics: Anti-Bacterial Agents; Clone Cells; Drug Resistance, Multiple, Bacterial; Electrophoresis, Polyacrylamide Gel; Erythromycin; Genes, Bacterial; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Spain; Streptococcus pneumoniae; Tetracycline Resistance | 2007 |
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
Topics: Adolescent; Adult; Ampicillin; Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactamases; Child; Child, Preschool; Female; Gene Frequency; Genotype; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Polymerase Chain Reaction; Respiratory Tract Infections | 2007 |
Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
Topics: Acetamides; Anti-Bacterial Agents; Daptomycin; Drug Resistance, Multiple, Bacterial; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enzyme Inhibitors; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Pyridines; Staphylococcus aureus; Thienopyridines; Thiophenes; Virginiamycin | 2007 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Geography; Haemophilus influenzae; Health Surveys; Humans; Moraxella catarrhalis; Penicillin Resistance; Respiratory Tract Infections; Streptococcus pneumoniae; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Infant; Infant, Newborn; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; RNA, Ribosomal, 23S | 2008 |
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Cloning, Molecular; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Multigene Family; Sequence Analysis, DNA; Substrate Specificity | 2008 |
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
Topics: Anti-Infective Agents; Bacteria; Community-Acquired Infections; Cross Infection; Enterococcus; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Respiratory System; Staphylococcus; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae | 2008 |
Antistreptococcal activity of AR-709 compared to that of other agents.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Pyrimidines; Streptococcus pneumoniae; Streptococcus pyogenes; Tetrahydrofolate Dehydrogenase; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Drug Resistance, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2008 |
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Topics: Aminopyridines; Anti-Bacterial Agents; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma hominis; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections | 2008 |
In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline; Mycobacterium; Mycobacterium Infections; Pigmentation; Species Specificity; Tigecycline | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Effect of DNase and antibiotics on biofilm characteristics.
Topics: Anti-Bacterial Agents; Biofilms; Colony Count, Microbial; Deoxyribonucleases; Dose-Response Relationship, Drug; Drug Combinations; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Plankton | 2009 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Ketolides; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections | 2009 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Macrolides; Microbial Sensitivity Tests; Penicillin G; Streptococcus pneumoniae; Streptococcus pyogenes; Triazoles | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
Topics: Ampicillin; Anti-Bacterial Agents; Cefotaxime; Erythromycin; Haemophilus influenzae; Lincosamides; Macrolides; Microbial Sensitivity Tests; Penicillins; Respiratory Tract Infections; Spain; Streptococcus pneumoniae; Streptococcus pyogenes; Streptogramin B | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Minocycline; Neisseria meningitidis; Penicillins; Rifampin; Sulfamethoxazole; Triazoles; Trimethoprim | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.
Topics: Anti-Infective Agents; Azithromycin; Chlamydia trachomatis; Clarithromycin; Doxycycline; Erythromycin; Genotype; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2010 |
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Biological Availability; Cyclophosphamide; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Lung; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutropenia; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections; Ribosomes; Sepsis; Stereoisomerism; Structure-Activity Relationship; Tetracycline Resistance; Tetracyclines | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).
Topics: Adenosine Triphosphatases; Amides; Animals; Anti-Bacterial Agents; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Knockout; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrroles; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2014 |
Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.
Topics: Anti-Bacterial Agents; Azithromycin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Escherichia coli; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2020 |
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Hep G2 Cells; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Quinolines; Streptococcus pneumoniae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Transcriptional Regulator ERG; Vancomycin-Resistant Enterococci | 2020 |
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Bites, Human; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Wound Infection | 1995 |
Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Clarithromycin; Erythromycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Streptococcus pneumoniae | 1996 |
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteriological Techniques; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Sensitivity and Specificity; Species Specificity; Streptococcus pneumoniae | 1997 |
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Bites and Stings; Bites, Human; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Species Specificity; Wound Infection | 1998 |
Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Erythromycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 1998 |
Activities of antimicrobial agents against intracellular pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Fluoroquinolones; Gentamicins; Humans; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Penicillin G; Quinolines; Rifampin; Streptococcus pneumoniae; Tumor Cells, Cultured | 2000 |
Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteremia; Drug Resistance, Microbial; Drug Resistance, Multiple; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2000 |
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Azithromycin; Body Weight; Fluoroquinolones; Gemifloxacin; Guinea Pigs; Half-Life; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Lung; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Survival Rate | 2001 |
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydophila pneumoniae; Clarithromycin; Cytokines; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Tumor Cells, Cultured | 2002 |
[Changes of antibody titers during antimicrobial therapy including levofloxacin for Chlamydia infections in the obstetrics and gynecology field].
Topics: Antibodies, Bacterial; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Drug Therapy, Combination; Female; Humans; Immunoglobulin G; Levofloxacin; Maternal-Fetal Exchange; Ofloxacin; Pregnancy; Pregnancy Complications, Infectious | 2002 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; United States | 2002 |
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chlamydophila pneumoniae; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rifamycins | 2003 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Emergency Service, Hospital; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2003 |
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Azithromycin; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Lactams; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Ofloxacin; Pneumococcal Infections; Prospective Studies; Respiratory Tract Infections; Streptococcus pneumoniae; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2003 |
Alterations in penicillin binding protein gene of Streptococcus pneumoniae and their correlation with susceptibility patterns.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Carrier Proteins; Clarithromycin; Drug Resistance, Bacterial; Genes, Bacterial; Hexosyltransferases; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Mutation; Ofloxacin; Penicillin G; Penicillin Resistance; Penicillin-Binding Proteins; Peptidyl Transferases; Pneumococcal Infections; Streptococcus pneumoniae; Thienamycins | 2003 |
[Detection of bacterial 16S rRAN gene in EPS of men with chronic pelvic pain syndrome and its clinical significance].
Topics: Anti-Bacterial Agents; Azithromycin; Chronic Disease; Humans; Levofloxacin; Male; Ofloxacin; Pelvic Pain; Polymerase Chain Reaction; Prostatitis; RNA, Bacterial; RNA, Ribosomal, 16S | 2003 |
[Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs].
Topics: Acute Disease; Ampicillin; Anti-Infective Agents; Azithromycin; Cefdinir; Cefpodoxime; Ceftizoxime; Cephalosporins; Clarithromycin; Enterobacteriaceae; Haemophilus influenzae; Humans; Levofloxacin; Ofloxacin; Penicillin G; Pharyngitis; Streptococcus pneumoniae; Streptococcus pyogenes; Tonsillitis | 2003 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chlamydophila pneumoniae; Folic Acid Antagonists; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pyrimidines | 2004 |
Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Cefaclor; Culture Media; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 2004 |
Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2004 |
Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Cell Line; Chlamydophila Infections; Chlamydophila pneumoniae; Dexamethasone; Drug Synergism; Glucocorticoids; Humans; Ketolides; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Ofloxacin | 2004 |
Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Animals; Azithromycin; Clavulanic Acid; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rats; Rats, Sprague-Dawley; Streptococcus pneumoniae | 2005 |
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Databases as Topic; Erythromycin; Female; Health Care Costs; Humans; Levofloxacin; Male; Managed Care Programs; Middle Aged; Models, Econometric; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Treatment Outcome | 2005 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Anticoagulants; Azithromycin; Cohort Studies; Drug Interactions; Female; Humans; International Normalized Ratio; Levofloxacin; Male; Ofloxacin; Platelet Aggregation Inhibitors; Prazosin; Retrospective Studies; Trimethoprim, Sulfamethoxazole Drug Combination; Warfarin | 2005 |
[Prevalence and treatment of pharyngeal Chlamydia trachomatis infections].
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Female; Humans; Japan; Levofloxacin; Ofloxacin; Pharyngitis; Prevalence; Sex Work; Sexual Behavior; Uterine Diseases | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Colistin; Dose-Response Relationship, Drug; Drug Synergism; In Vitro Techniques; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Mutation; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 2006 |
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2006 |
Occurrence of levofloxacin, clarithromycin and azithromycin in wastewater treatment plant in Japan.
Topics: Anti-Bacterial Agents; Azithromycin; Chromatography, Liquid; Clarithromycin; Conservation of Natural Resources; Japan; Levofloxacin; Mass Spectrometry; Ofloxacin; Sewage; Time Factors; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Purification | 2006 |
Severe Legionnaires' disease successfully treated with levofloxacin and azithromycin.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combination; Female; Humans; Legionnaires' Disease; Levofloxacin; Lung; Middle Aged; Ofloxacin; Radiography; Remission Induction | 2006 |
Multidrug-induced erythema multiforme.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Ceftriaxone; Ciprofloxacin; Drug Hypersensitivity; Erythema Multiforme; Female; Humans; Levofloxacin; Methenamine; Ofloxacin; Piroxicam; Skin Tests; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2007 |
Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Creatinine; Diabetes Complications; Female; Fluoroquinolones; Gatifloxacin; Hospitals, Veterans; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Medical Records; Middle Aged; Multivariate Analysis; Ofloxacin; Prevalence; Retrospective Studies; Rhode Island; Risk Factors | 2008 |
Onset of symptom resolution in adults with acute bacterial rhinosinusitis treated with a single dose of azithromycin extended release compared with 10 days of levofloxacin: a retrospective analysis of a randomized, double-blind, double-dummy trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Randomized Controlled Trials as Topic; Retrospective Studies; Rhinitis; Sinusitis; Treatment Outcome | 2007 |
Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clavulanic Acid; Computer Simulation; Drug Resistance, Bacterial; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 2007 |
[Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bronchitis, Chronic; Clarithromycin; Female; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Ofloxacin; Treatment Outcome; Young Adult | 2007 |
Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Female; Health Resources; Humans; Least-Squares Analysis; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Practice Guidelines as Topic; Societies, Medical; United States | 2009 |
[Voice on the treatment of ureaplasmas infections].
Topics: Anti-Infective Agents; Azithromycin; Dose-Response Relationship, Drug; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Ureaplasma; Ureaplasma Infections; Ureaplasma urealyticum | 2009 |
Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Doxycycline; Drug Resistance, Multiple, Bacterial; Humans; Kentucky; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Outcome; United States | 2002 |
Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Chi-Square Distribution; Clarithromycin; Community-Acquired Infections; Female; Humans; Kaplan-Meier Estimate; Legionella pneumophila; Legionnaires' Disease; Length of Stay; Levofloxacin; Male; Ofloxacin; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
[Clinical features and delayed aftereffects of Legionellosis pneumonia during an epidemic outbreak].
Topics: Anti-Bacterial Agents; Azithromycin; Disease Outbreaks; Female; Humans; Legionellosis; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Russia; Treatment Outcome; Water Supply | 2010 |
Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Drug Therapy, Combination; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prostate-Specific Antigen; Prostatitis; Semen; Urethra | 2010 |
Clinical efficacy of levofloxacin 500 mg once daily for 7 days for patients with non-gonococcal urethritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Humans; Leukocyte Count; Levofloxacin; Male; Middle Aged; Mycoplasma genitalium; Mycoplasma Infections; Ofloxacin; Treatment Outcome; Ureaplasma Infections; Ureaplasma urealyticum; Urethritis; Young Adult | 2011 |
In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged-Ring Compounds; Cell Line; Cells, Cultured; Clarithromycin; Disease Models, Animal; Humans; Ketolides; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Macrolides; Mice; Microbial Sensitivity Tests; Ofloxacin | 2011 |
Antibacterial and synergy of a flavanonol rhamnoside with antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Ceftazidime; Drug Synergism; Flavonols; Glycosides; Humans; Hypericum; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Ofloxacin; Quercetin; Sputum | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Erythromycin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Roxithromycin; Tetracycline; Time Factors; Ureaplasma Infections; Ureaplasma urealyticum | 2011 |
Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Berberine; Cefazolin; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Bacterial; Drug Synergism; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Ofloxacin | 2012 |
Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chloramphenicol; Drug Resistance; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Netilmicin; Quinolines; Staphylococcus epidermidis; Tobramycin; Vancomycin | 2013 |
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.
Topics: Azithromycin; Humans; Levofloxacin; NF-kappa B; Pulmonary Disease, Chronic Obstructive; Quality of Life; Sarcoidosis, Pulmonary | 2013 |
[Questionnaire survey on medical care for male urethritis in community clinics in Shiga prefecture].
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Drug Administration Schedule; Drug Utilization; Female; Gonorrhea; Health Knowledge, Attitudes, Practice; Humans; Japan; Levofloxacin; Male; Nucleic Acid Amplification Techniques; Patient Care; Practice Guidelines as Topic; Sexual Partners; Sexually Transmitted Diseases, Bacterial; Specialization; Surveys and Questionnaires; Urethritis | 2014 |
In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Chlamydia trachomatis; Chlamydophila pneumoniae; DNA Gyrase; Doxycycline; Isoxazoles; Levofloxacin; Microbial Sensitivity Tests; Morpholines; Oxazolidinones; Spiro Compounds; Topoisomerase II Inhibitors | 2014 |
In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates.
Topics: Anti-Bacterial Agents; Azithromycin; Bridged Bicyclo Compounds, Heterocyclic; Humans; Hydroxamic Acids; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Microbial Sensitivity Tests | 2015 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Doxycycline; Humans; Isoxazoles; Levofloxacin; Microbial Sensitivity Tests; Morpholines; Mycoplasma; Mycoplasma genitalium; Mycoplasma pneumoniae; Oxazolidinones; Spiro Compounds; Ureaplasma | 2015 |
Hemoptysis and Progressive Dyspnea in a 67-Year-Old Woman with History of Renal Transplantation.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Biopsy; Bronchi; Bronchography; Diagnosis, Differential; Dyspnea; Female; Hemoptysis; Humans; Kidney Transplantation; Levofloxacin; Malacoplakia; Tomography, X-Ray Computed | 2016 |
Factors Associated With Primary Care Physician Knowledge of the Recommended Regimen for Treating Gonorrhea.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Chi-Square Distribution; Clinical Protocols; Drug Therapy, Combination; Female; Gonorrhea; Health Knowledge, Attitudes, Practice; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Physicians, Primary Care; Practice Patterns, Physicians'; Primary Health Care; Spectinomycin | 2017 |
Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Female; Humans; Legionnaires' Disease; Length of Stay; Levofloxacin; Male; Middle Aged; Propensity Score; Retrospective Studies; Spain; Treatment Outcome | 2017 |
Haemophilus influenzae Isolated From Men With Acute Urethritis: Its Pathogenic Roles, Responses to Antimicrobial Chemotherapies, and Antimicrobial Susceptibilities.
Topics: Acute Disease; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Chlamydia Infections; Chlamydia trachomatis; Coinfection; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gonorrhea; Haemophilus influenzae; Humans; Leukocyte Count; Levofloxacin; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Retrospective Studies; Urethritis | 2017 |
Antibiotic Therapy for Acute Watery Diarrhea and Dysentery.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Developing Countries; Diarrhea; Dysentery; Humans; Levofloxacin; Military Personnel; Rifamycins; Rifaximin | 2017 |
Appraisal of the cardiovascular risks of azithromycin: an observational analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cardiovascular Diseases; Clarithromycin; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Risk Factors; Young Adult | 2017 |
Diagnostic Accuracy of Global Pharma Health Fund Minilab™ in Assessing Pharmacopoeial Quality of Antimicrobials.
Topics: Amoxicillin; Anti-Infective Agents; Azithromycin; Cefuroxime; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; False Negative Reactions; False Positive Reactions; Levofloxacin; Metronidazole; Quality Control; Reproducibility of Results | 2018 |
Impact of an antimicrobial stewardship program on outcomes in patients with community-acquired pneumonia admitted to a tertiary community hospital.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Azithromycin; Ceftriaxone; Community-Acquired Infections; Female; Hospitals, Community; Humans; Length of Stay; Levofloxacin; Male; Pneumonia, Bacterial; Retrospective Studies; Tertiary Care Centers; Treatment Outcome | 2018 |
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Chlamydial Pneumonia; Chlamydophila pneumoniae; Doxycycline; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Tetracyclines | 2019 |
An adult case of severe life-threatening Mycoplasma pneumoniae pneumonia due to a macrolide-resistant strain, Japan: a case report.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Drug Resistance, Bacterial; Female; Humans; Japan; Levofloxacin; Macrolides; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; RNA, Ribosomal, 23S; Tetracycline | 2019 |
Levofloxacin for NIH Category II Chronic Bacterial Prostatitis: A Real-Life Study.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Candida albicans; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Middle Aged; National Institutes of Health (U.S.); Prostate; Prostate-Specific Antigen; Prostatitis; Retrospective Studies; Treatment Outcome; United States; Young Adult | 2019 |
Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Japan; Levofloxacin; Male; Middle Aged; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome | 2019 |
Prevalence of genital Mycoplasma and response to eradication treatment in patients undergoing assisted reproductive techniques.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clindamycin; Doxycycline; Embryo Implantation; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Mycoplasma hominis; Mycoplasma Infections; Prevalence; Real-Time Polymerase Chain Reaction; Reproductive Techniques, Assisted; Semen Analysis; Sex Factors; Treatment Outcome; Ureaplasma Infections; Ureaplasma urealyticum; Young Adult | 2019 |
Topics: Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Carrier State; Child, Preschool; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Mycoplasma pneumoniae; Pneumonia, Bacterial; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Ribosomal, 23S | 2019 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |
Assessment of the in vitro activity of azithromycin niosomes alone and in combination with levofloxacin on extensively drug-resistant Klebsiella pneumoniae clinical isolates.
Topics: Anti-Bacterial Agents; Azithromycin; Drug Compounding; Drug Resistance, Multiple, Bacterial; Drug Synergism; Klebsiella pneumoniae; Levofloxacin; Liposomes; Microbial Sensitivity Tests | 2021 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multiple, Bacterial; Ertapenem; Gentamicins; Gonorrhea; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Neisseria gonorrhoeae | 2021 |
Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Death, Sudden, Cardiac; Fluoroquinolones; Humans; Levofloxacin; Renal Dialysis; Renal Insufficiency; United States | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Azithromycin; Bacillus anthracis; Clarithromycin; Disease Models, Animal; Levofloxacin; Macaca fascicularis; Respiratory Tract Infections | 2022 |
[The problem of formation of new risks of medicinal resistance of patients with tuberculosis in condition of active use of antibiotics by population under COVID-19].
Topics: Anti-Infective Agents; Antitubercular Agents; Azithromycin; COVID-19; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mycobacterium tuberculosis; Pandemics; Quinolones; Tuberculosis | 2023 |
Antibiotic susceptibility pattern of Portuguese environmental Legionella isolates.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Doxycycline; Fluoroquinolones; Humans; Legionella; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Microbial Sensitivity Tests; Portugal | 2023 |
[Prescription of antibiotics in acute respiratory infections non-pneumonia in a private outpatient practice].
Topics: Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Drug Prescriptions; Female; Humans; Levofloxacin; Male; Outpatients; Practice Patterns, Physicians'; Respiratory Tract Infections; Retrospective Studies | 2022 |
Molecular characterization of multidrug-resistant non-typeable Haemophilus influenzae with high-level resistance to cefuroxime, levofloxacin, and trimethoprim-sulfamethoxazole.
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Azithromycin; beta-Lactamases; Cefuroxime; Ciprofloxacin; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2023 |